$0.00
0.00%
Nasdaq, Wed, Dec 25 2024
ISIN
US2123261024
Symbol
CFRX
Sector
Industry

ContraFect Corp. Stock price

$0.00
+0.00 0.00% 1M
-0.02 99.53% 6M
-0.03 99.67% YTD
-0.03 99.64% 1Y
-215.20 100.00% 3Y
-405.84 100.00% 5Y
-3,192.56 100.00% 10Y
Nasdaq, Closing price Wed, Dec 25 2024
+0.00 0.00%
ISIN
US2123261024
Symbol
CFRX
Sector
Industry

Key metrics

Market capitalization $0.00
Enterprise Value $-2.86m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.08
P/B ratio (TTM) P/B ratio 0.00
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-30.21m
Free Cash Flow (TTM) Free Cash Flow $-35.65m
Cash position $5.41m
EPS (TTM) EPS $-19.27
Short interest 2.75%
Show more

Is ContraFect Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ContraFect Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ContraFect Corp.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast ContraFect Corp.:

Buy
100%

Financial data from ContraFect Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
- -
-
100%
- Direct Costs 0.16 0.16
7% 7%
-
-0.16 -0.16
7% 7%
-
- Selling and Administrative Expenses 11 11
9% 9%
-
- Research and Development Expense 18 18
64% 64%
-
-30 -30
53% 53%
-
- Depreciation and Amortization 0.16 0.16
7% 7%
-
EBIT (Operating Income) EBIT -30 -30
53% 53%
-
Net Profit -24 -24
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about ContraFect Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Head office United States
CEO Michael Messinger
Founded 2008
Website www.contrafect.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today